Caristo Diagnostics Welcomes Stephen Deitsch as New CEO to Drive Growth in Cardiovascular AI Technology

Leadership Change at Caristo Diagnostics

In a significant move poised to strengthen its industry standing, Caristo Diagnostics, a notable spinout from the University of Oxford renowned for its pioneering AI technology focused on cardiovascular disease, has named Stephen Deitsch as its new Chief Executive Officer (CEO). This strategic appointment, effective immediately, marks a pivotal moment in the company's growth trajectory.

Extensive Medtech Experience

Steve Deitsch brings to Caristo an impressive repertoire of over 25 years of leadership experience within the medtech and healthcare sectors. His previous tenure as Chief Financial Officer at OrganOx was highlighted by the company's successful $1.5 billion sale to Terumo Corporation in 2025, setting a record for one of the largest exits from the University of Oxford. As Deitsch steps into the CEO role at Caristo, he follows in the footsteps of Frank Cheng, who navigated the company as CEO since 2023 and now transitions to Chief Operating Officer.

Vision for Innovation

In response to his appointment, Deitsch expressed his enthusiasm about joining Caristo during a transformative phase for cardiovascular disease management. He emphasized the importance of focusing on coronary inflammation, which significantly contributes to heart attacks. Deitsch stated, "At Caristo, we have pioneered the first AI technology capable of detecting coronary inflammation and stratifying cardiovascular risk. In the hands of skilled clinicians worldwide, this innovation has the potential to shift care from a reactive to a truly preventive model, ultimately improving patient outcomes."

This vision reflects Caristo’s broader mission. The company has already made notable advancements with its revolutionary inflammation detection technology termed CaRi-Heart®, which is currently commercially available in the UK, Europe, and Australia. Following the American Medical Association's introduction of new Category III CPT codes for CaRi-Heart, the company is eagerly awaiting FDA clearance to further expand its impact in the U.S. healthcare market.

Addressing Cardiovascular Risks

Caristo Diagnostics is committed to collaborating with physicians, hospitals, research institutions, and pharmaceutical partners to facilitate early detection of heart disease. Its innovative approach aims to identify individuals at risk of heart attacks even before symptoms appear, thereby advancing personalized prevention strategies. According to Chairman Michel Lussier, Deitsch's deep understanding of the medtech landscape and strategic financial insight makes him ideally suited to guide Caristo through its next growth phase.

Future Endeavors

As Caristo moves forward, the company continues to focus on expanding its AI technology’s global reach to create substantial value for patients, healthcare providers, and shareholders alike. The leadership transition is expected to infuse fresh energy into the company’s dynamics while continuing to build upon the solid foundations laid by Cheng.

The future for Caristo Diagnostics appears promising with Deitsch at the helm, aiming to enhance preventive care in cardiovascular health through cutting-edge AI applications. The industry will certainly keep a close watch on how these developments unfold under his leadership.